Meeting
2013 ASCO Annual Meeting
Impact of BRAF mutation and effectiveness of BRAF inhibitor on the brain metastases in patients with metastatic melanoma.
Authors
Tulasi Gummadi
University of Minnesota, Minneapolis, MN
Tulasi Gummadi , Roxana Stefania Dronca , Chul Kim , Lisa A. Kottschade , Rajendar K Mittapalli , William F. Elmquist , Arkadiusz Dudek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9048)
DOI
10.1200/jco.2013.31.15_suppl.9048
Abstract #
9048
Poster Bd #
45C
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Impact of immune checkpoint and BRAF inhibitors on the incidence of second primary malignancies (SPM) in melanoma.
First Author: Nibash Budhathoki
Poster
2019 ASCO Annual Meeting
Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC.
First Author: Marcelo Vailati Negrao
Poster
2016 ASCO Annual Meeting
Co-targeting BRAF with mTOR inhibition in solid tumors harboring BRAF mutations: A phase I study.
First Author: Shiraj Sen
Poster
2016 ASCO Annual Meeting
Influence of melanocortin-1 receptor (MC1R) polymorphisms on clinical outcomes of patients with metastatic melanoma harboring the BRAF mutation and treated with BRAF inhibitors.
First Author: Sabino Strippoli